Clinical Trial Update: Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial of PB-119 given subcutaneously weekly vs placebo in drug-naïve type 2 diabetes patients completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PB-119 (PB-119)

Snippet

Sponsor: PegBio Co., Ltd. | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED